Icon, which provides services to the pharmaceutical, biotechnology and medical device industries, has bought Oxford Outcomes for an undisclosed sum.
The deal will boost Icon's late phase and outcome research services to meet growing demand for more outsourced expertise in this market.
Headquartered in the UK and with offices in the US and Canada, Oxford has a workforce of about 78. These workers will transfer to Icon when the deal is complete.
'Oxford brings to Icon a wealth of expertise in the fields of health economics, outcomes research and a strong reputation for excellent client service,' commented Icon's chief executive Peter Gray.
